Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLG | P00747 | 1/20 | 0.49 |
| ▸ | KRAS | P01116 | 2/20 | 0.47 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.46 |
| ▸ | OXTR | P30559 | 1/20 | 0.46 |
| ▸ | GRB2 | P62993 | 1/20 | 0.45 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.44 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.44 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.44 |
| ▸ | ELANE | P08246 | 4/20 | 0.44 |
| ▸ | CIB1 | Q99828 | 1/20 | 0.44 |
| ▸ | NTSR1 | P30989 | 4/20 | 0.43 |
| ▸ | ALB | P02768 | 1/20 | 0.43 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29884013 | 1.00 | PLG (0.49) | PLGKRASHDAC4OXTRGRB2 | |
| SCHEMBL29740322 | 1.00 | PLG (0.49) | PLGKRASHDAC4OXTRGRB2 | |
| SCHEMBL29773718 | 1.00 | PLG (0.49) | PLGKRASHDAC4OXTRGRB2 | |
| SCHEMBL30928172 | 1.00 | PLG (0.49) | PLGKRASHDAC4OXTRGRB2 | |
| SCHEMBL29773738 | 0.97 | PLG (0.52) | PLGKRASHDAC4OXTRHDAC3 | |
| SCHEMBL22725808 | 0.97 | KRAS (0.49) | PLGKRASHDAC4OXTRGRB2 | |
| SCHEMBL30038886 | 0.95 | PLG (0.49) | PLGKRASHDAC4OXTRHDAC3 | |
| SCHEMBL29773704 | 0.94 | KRAS (0.49) | PLGKRASHDAC4OXTRGRB2 | |
| SCHEMBL29773696 | 0.94 | KRAS (0.49) | PLGKRASHDAC4OXTRGRB2 | |
| SCHEMBL29390495 | 0.94 | KRAS (0.49) | PLGKRASHDAC4OXTRGRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 360 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4702355-A1 | PROTEIN FREE SOLUTION FOR STABILIZING IMMUNOASSAY CALIBRATORS | Beckman Coulter, Inc. (US) | 2026-03-04 | — | — | EP | claimed |
| EP-4637348-A1 | DOUBLE ENCAPSULATED NANOCOMPOSITE FOR STAGED DELIVERY OF ACTIVE INGREDIENT(S), AND A METHOD OF PRODUCING THEREOF | Council Of Scientific & Industrial Research (IN) | 2025-10-29 | — | — | EP | claimed |
| US-20250313596-A1 | BACILLUS SUBTILIS STRAINS PRODUCING NEW MYCOSUBTILIN ISOFORMS | LIPOFABRIK (FR) | 2025-10-09 | — | — | US | claimed |
| EP-4626909-A1 | NEW BACILLUS SUBTILIS STRAINS PRODUCING NEW MYCOSUBTILIN ISOFORMS | Lipofabrik (FR) | 2025-10-08 | — | — | EP | claimed |
| US-20250295748-A1 | TREATMENT AND PREVENTION OF VIRAL INFECTIONS | SPOREGEN LIMITED (GB) | 2025-09-25 | — | — | US | claimed |
| EP-3755357-B1 | AN ANTIBIOTIC COMPOSITION COMPRISING MICELLES | SPOREGEN LTD (GB) | 2025-09-17 | — | — | EP | claimed |
| WO-2025084927-A1 | MYCOSUBTILIN IN BAKERY PRODUCTS | MAURI TECHNOLOGY B.V. (NL) | 2025-04-24 | — | — | WO | claimed |
| US-20250034547-A1 | COMPOSITIONS AND METHODS FOR THE PURIFICATION AND CONCENTRATION OF NUCLEIC ACIDS FROM LARGE-VOLUME SAMPLES | PROMEGA CORPORATION | 2025-01-30 | — | — | US | claimed |
| WO-2025024643-A1 | COMPOSITIONS AND METHODS FOR THE PURIFICATION AND CONCENTRATION OF NUCLEIC ACIDS FROM LARGE-VOLUME SAMPLES | PROMEGA CORPORATION (US) | 2025-01-30 | — | — | WO | claimed |
| US-12171734-B2 | Pathogenic bacteria | SPOREGEN LIMITED (GB) | 2024-12-24 | — | — | US | claimed |
| US-20230136991-A1 | ITURIN FAMILY LIPOPEPTIDES IN PEST CONTROL | INSTITUTE OF BIOLOGY, HEBEI ACADEMY OF SCIENCES (CN) | 2023-05-04 | — | — | US | claimed |
| EP-4168055-A1 | OXINE-CONTAINING CELL RADIOLABELLING AGENTS | King's College London (GB) | 2023-04-26 | — | — | EP | claimed |
| EP-4097293-A1 | SEPARATION OF POLYCOTTON BLENDS | Infinited Fiber Company Oy (FI) | 2022-12-07 | — | — | EP | claimed |
| US-11512280-B2 | Method for culturing spore-forming bacteria, and method for producing useful substance | SDS BIOTECH K.K. (JP) | 2022-11-29 | — | — | US | claimed |
| WO-2022228058-A1 | APPLICATION OF ITURIN FAMILY LIPOPEPTIDES IN PEST CONTROL | 河北省科学院生物研究所 | 2022-11-03 | — | — | WO | claimed |
| US-11453818-B2 | Composition and methods for enhancing the production of hydrocarbons | NEXTIER COMPLETION SOLUTIONS INC. (US) | 2022-09-27 | — | — | US | claimed |
| US-20220259626-A1 | GENERATION OF ACYL AMINO ACIDS | MODULAR GENETICS, INC. | 2022-08-18 | — | — | US | claimed |
| WO-2022076877-A1 | AGRICULTURAL BIOPOLYMER COATING PLATFORM | AGROSPHERES, INC. (US) | 2022-04-14 | — | — | WO | claimed |
| WO-2022049381-A1 | TREATMENT AND PREVENTION OF VIRAL INFECTIONS | SPOREGEN LIMITED (GB) | 2022-03-10 | — | — | WO | claimed |
| WO-2022040799-A1 | ANTIMICROBIAL COMPOSITION | GP TECH INOVASYON TEKNOLOJI VE ARASTIRMA A.S (TR) | 2022-03-03 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12171734-B2 | Pathogenic bacteria | CLPP, CLPX, ANTXR2 | PLG 2209/4885KRAS 3299/4885HDAC4 379/4885 |
| US-20220259626-A1 | GENERATION OF ACYL AMINO ACIDS | FADS1, FADS2, FAR1 | PLG 1385/4885KRAS 973/4885HDAC4 3730/4885 |
| US-20250295748-A1 | TREATMENT AND PREVENTION OF VIRAL INFECTIONS | TLR3, TLR5, IRF3 | PLG 4714/4885KRAS 2371/4885HDAC4 1528/4885 |
| US-20250313596-A1 | BACILLUS SUBTILIS STRAINS PRODUCING NEW MYCOSUBTILIN ISOFORMS | BBC3, BYSL, BCL2L11 | PLG 2280/4885KRAS 2589/4885HDAC4 3217/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.